|Bid||51.90 x 1300|
|Ask||51.96 x 1400|
|Day's Range||51.63 - 52.23|
|52 Week Range||36.15 - 64.94|
|Beta (5Y Monthly)||0.22|
|PE Ratio (TTM)||63.48|
|Forward Dividend & Yield||1.40 (2.71%)|
|Ex-Dividend Date||Aug 13, 2020|
|1y Target Est||N/A|
The race for a COVID-19 vaccine race doesn't end with emergency use application. Companies are faced with several obstacles, according to the FDA's vaccine advisory committee.
The leader of the government’s vaccine program, Robert Johnson, recounted efforts that have compressed the usual timetable for delivering a vaccine.
Clinical studies on coronavirus vaccine candidates of AstraZeneca (AZN) and J&J (JNJ) which were paused for reviewing adverse events are anticipated to resume as early as this week.